Funding Details
- Awarder
- SOSV
- Date Award
- May 13, 2024
- Vertical
- Biopharma
- Funding URL
- View Funding Page
Company Info
- Traction
- None
- Organizations Involved
- None
- Founders
- Paul Blum, Benjamin Pavlik
- Company Description
- Neurocarrus is developing a novel drug and delivery technology to treat chronic pain without addiction or disruption of muscular control. Neurocarrus is developing a novel therapy to treat pain without addiction.
We are a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control. Our first-in-class therapeutic (N-001) is designed to treat the physiological symptoms of pain without invasive surgical procedures or systemically absorbed drugs.
We engineered N-001 for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute nerve damage. N-001 is a leading technology in the fight against the prescription opioid abuse and heroin epidemic, which claims the lives of tens of thousands of Americans each year. A safe, non-addictive and effective treatment for pain (a disease burden of over $635 billion in the US*) would have a major impact on human health.
Neurocarrus was founded by prominent research scientists in the field of protein engineering. The company is led by a strong management and advisory team with expertise in business, biotechnology and medicine. To date, we have generated extensive in vitro and in vivo data supporting the efficacy of N-001.
- Market
- Human Health
- Location
-
United States
- Coinvestors
- None
Links